January 22, 2024
Weil is representing Cynosure and its sponsor-owner CD&R in its definitive merger agreement with Lutronic, a portfolio company of Hahn & Co. Both Cynosure and Lutronic are global providers of energy-based medical aesthetic treatment systems and related technologies. The transaction is expected to close in the first quarter of 2024.
With an over 30-year history of science-driven innovation, Cynosure is a leading provider of medical aesthetic treatment systems that enable dermatologists, plastic surgeons, medical spas, and other healthcare practitioners to perform non-invasive and minimally invasive procedures. For over two decades, Lutronic has been a global leader in the development of intelligent laser and energy-based systems.
The Weil team advising Cynosure is led by Private Equity partners Robert Rizzo and Arnie Fridhandler and includes Private Equity associates Larissa Lucas, Dave Rossetti, Adam Voorberg and Juliet Sato (Not Yet Admitted in New York); Tax partners Graham Magill and Stuart Goldring, counsel Kevin Donegan and Blake Bitter and associate Sydnei Jones; Banking & Finance partner Paul Overmyer and associate Yan Li; Executive Compensation & Benefits Chair Paul Wessel and associates Amanda Nowak and Sanjana Rao; Employment partner Peter Mee, counsel Mark Taylor and associate Nicole Jibrine; Real Estate partner Jannelle Marie Seales and associate Ilana Bier; Environmental Head Annemargaret Connolly; Regulatory Transactions partners Shawn Cooley, John O'Loughlin, Matthew Morton and Timothy Welch, counsel Ariel Fliman and associate Christina Carone; and Technology & IP Transactions partners Barry Fishley, Olivia Greer and Dennis Adams, counsel Kane Wishart and associates Amanda DeMasi, Alexis Bello, Adeline Park, David Merck and Audrey Nicolson.